Petrelintide: Dose References, ZUPREME Data & Safety

Quick Reference Card

Contradictions and open gaps

ZUPREME-1 counts differ by context. Roche describes 493 people in the trial, while Zealand's ADA release says 485 adults were randomized. The likely distinction is enrolled versus randomized or analysis population, but the exact reconciliation should wait for the full publication. [3][5]

The most important public dose gap is the ZUPREME-1 milligram table. The study clearly used five once-weekly dose levels with 4-week escalation, but the opened primary sources did not publish the exact amounts for those five arms. Phase 1 targets of 2.4, 4.8 and 9.0 mg should not be silently mapped onto ZUPREME-1 dose groups. [1][3]

What is petrelintide?

Petrelintide is an investigational amylin analog designed for once-weekly subcutaneous use. Amylin is co-secreted with insulin by pancreatic beta cells after nutrient intake and participates in satiety signaling. Petrelintide is positioned as an alternative or partner to GLP-1-based weight-management therapies rather than as another GLP-1 receptor agonist. [2][3]

The compound was designed for potency, chemical stability and physical stability near neutral pH. Zealand describes this as relevant for co-formulation or co-administration with other peptides. That property supports development strategy; it does not prove that unsupervised combinations are safe or effective. [2][6]

Mechanism and evidence balance

Schematic illustration; receptor shapes are symbolic. The mechanism does not establish a dose or predict an individual outcome.

Petrelintide works through amylin receptor biology, not GLP-1 receptor agonism. Public sponsor materials emphasize satiety and potential leptin-sensitivity effects. The medicinal chemistry publication frames amylin as a physiological satiety signal and describes petrelintide as a stable, long-acting human amylin analog. [2][6]

Human evidence is still early but meaningful: phase 1 dose escalation has been published, and ZUPREME-1 has phase 2 topline and ADA 2026 data. Preclinical and formulation work explains why the molecule can be developed as a weekly peptide and possible combination partner. Claims about lean-mass preservation remain less mature than body-weight and tolerability data; they should not be written as established clinical benefit without body-composition results from completed human trials. [2][5][6]

Research and clinical evidence

Phase 1 published trials

The published phase 1 program included single-dose and multiple-dose trials. In the multiple ascending-dose part that most resembles weight-management development, once-weekly injections were escalated to 2.4, 4.8 and 9.0 mg targets over 16 weeks. Petrelintide was slowly absorbed, had an approximate 10-day half-life, showed dose-proportional steady-state exposure, and produced up to 8.6% body-weight reduction after 16 weeks. [1]

Tolerability in phase 1 was notable because gastrointestinal events were generally mild. In the 16-week higher-dose part, nausea occurred in 16.7% to 33.3% of petrelintide participants versus 16.7% with placebo, diarrhea was rare, and vomiting occurred only in the participant who discontinued due to GI events. These numbers came from small cohorts and should not be generalized as final safety rates. [1]

ZUPREME-1 obesity trial

ZUPREME-1 was a randomized, double-blind, placebo-controlled phase 2 dose-finding trial in people with obesity or overweight with weight-related comorbidities. Roche described 493 participants, mean BMI around 37 kg/m2, and a gender-balanced trial population. Zealand's June 2026 ADA release described 485 randomized adults, 53% female, mean age 47 years, BMI 36.7 kg/m2 and body weight 107.1 kg. [3][5]

The study compared five once-weekly petrelintide dose levels with placebo, added to reduced-calorie diet and increased physical activity. The primary endpoint was percent change in body weight at week 28. Weight change continued through week 42, reaching up to 10.7% mean loss with petrelintide versus 1.7% with placebo by the efficacy estimand. [3][5]

The tolerability signal was central to the sponsor narrative. Zealand reported that 88% to 98% of participants successfully escalated to their targeted maintenance dose, most GI events were mild, nausea occurred in 19.6% on petrelintide versus 6.2% on placebo, vomiting was 3.0% versus 6.2%, and discontinuation due to GI adverse events was 1.5% with petrelintide. Roche reported no vomiting and no GI-related discontinuations in the maximally effective arm. These statements are sponsor communications until the full dataset is published. [3][5]

Development status

Zealand's pipeline page states that petrelintide will advance into phase 3 clinical trials for chronic weight management, with initiation planned in the second half of 2026. The same page lists ZUPREME-2 as the phase 2 trial in overweight or obesity with type 2 diabetes, with topline results expected in the second half of 2026. [2]

Roche and Zealand also plan combination development with CT-388, Roche's incretin asset. Combination rationale does not establish safety for unofficial stacking. It only shows the sponsor's controlled clinical-development direction. [2][3]

ZUPREME-2 was marked completed on August 13, 2026 in the registry update posted September 9. The checked record has no posted results and still masks the three milligram targets. [8]

Safety and tolerability

Public materials emphasize a favorable gastrointestinal profile compared with expectations for some incretin therapies, but petrelintide remains investigational. Phase 1 cohorts were small, ZUPREME-1 is not yet fully published, and rare adverse events require larger and longer exposure.

Known tolerability topics to track include nausea, vomiting, diarrhea, constipation, early fullness, reduced intake, dehydration risk during appetite suppression, gallbladder events and treatment discontinuation. The available evidence does not establish safety in pregnancy, eating disorders, advanced gastrointestinal disease, severe renal or hepatic impairment, or combinations with GLP-1/GIP/GLP-1-glucagon agonists outside trials.

Administration and tracking

The public phase 1 schedule and ZUPREME-1 schedule differ. Phase 1 part 2 escalated every 2 weeks to 2.4, 4.8 or 9.0 mg targets. ZUPREME-1 escalated every 4 weeks and used five masked dose levels. A protocol record should keep the schedule, route, formulation and population attached to the dose number.

Doserly can track injection day, titration holds, nausea, fullness, weight trend, waist trend, protein intake, activity and adverse symptoms. Tracking creates an organized record; it does not validate petrelintide use or determine an appropriate dose.

What to monitor in the evidence

The next high-value source is the full ZUPREME-1 publication or congress table with dose-by-dose milligram labels, efficacy by arm and body-composition findings. ZUPREME-2 results will show whether the profile changes in people with type 2 diabetes. Phase 3 registry records should clarify dose selection and target population.

Frequently asked questions

Is petrelintide a GLP-1 drug?

No. Petrelintide is an amylin analog. It may affect satiety and weight, but it is not a GLP-1 receptor agonist. [2][6]

Is petrelintide approved?

No. Petrelintide is investigational and has not been approved for marketing by a regulatory authority in the sources reviewed. [2]

What dose of petrelintide has been studied?

Published phase 1 data include single subcutaneous doses up to 2.4 mg and weekly repeated-dose targets up to 9.0 mg. ZUPREME-1 used five weekly dose levels with 4-week escalation, but public materials opened for this review did not disclose the complete milligram table. [1][3][5]

Does ZUPREME-1 prove petrelintide is better tolerated than GLP-1 drugs?

No direct broad conclusion is established. ZUPREME-1 sponsor communications report low GI discontinuation and favorable tolerability versus placebo, but comparisons with GLP-1 drugs require matched head-to-head data or careful cross-trial framing. [3][5]

Can petrelintide be combined with incretin drugs?

Sponsors are planning controlled combination studies, including with CT-388. That is different from unmonitored stacking. Safety, dose selection and sequencing need trial evidence. [2][3]

Sources & References

[1] Olsen et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide for weight management. Diabetes, Obesity and Metabolism, 2026. DOI: 10.1111/dom.70753.

[2] Zealand Pharma. Petrelintide pipeline page. Reviewed September 12, 2026.

[3] Roche. Positive Phase II results for petrelintide, ZUPREME-1. March 5, 2026.

[4] ClinicalTrials.gov. ZUPREME-1, NCT06662539.

[5] Zealand Pharma. New data from Phase 2 ZUPREME-1 at ADA 2026. June 5, 2026.

[6] Munch et al. Development of petrelintide: a potent, stable, long-acting human amylin analogue. Journal of Medicinal Chemistry, 2025. DOI: 10.1021/acs.jmedchem.5c01185.

[7] PeptIQ. Petrelintide dosing guide. Popular educational guide, August 2, 2026; included for attribution and missing-dose caution, not clinical authority.

[8] ClinicalTrials.gov. ZUPREME-2, NCT06926842. Registry update September 9, 2026.

Related peptide guides

• Cagrilintide: another long-acting amylin analog program.
• Zenagamtide: GLP-1/amylin unimolecular program.
• Semaglutide: GLP-1 comparator context.
• Tirzepatide: dual GIP/GLP-1 comparator context.
• GLP-1 weight-management guide: category-level comparison.